Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
Go back to Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial| Novori, Inc. (AMEX: NOVO) | Delayed: 0.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.01 | 52 Week High | $0.23 | |||
| Open | $0.01 | 52 Week Low | $0.01 | |||
| Day High | $0.01 | P/E | N/A | |||
| Day Low | $0.01 | EPS | $-0.01 | |||
| Volume | 63,422 | |||||
| NOVO-NORDISK A/S (NYSE: NVO) | Delayed: 46.60 -0.91 (1.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $47.51 | 52 Week High | $59.00 | |||
| Open | $46.35 | 52 Week Low | $32.80 | |||
| Day High | $46.74 | P/E | N/A | |||
| Day Low | $46.04 | EPS | $0.00 | |||
| Volume | 6,219,249 | |||||
